This story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine, which relaunched today. Sign up here to receive it in your inbox.

Rep. Elijah Cummings, the Maryland Democrat chairing the House Oversight Committee, put the pharmaceutical industry on notice this week when he launched an investigation into the industry’s drug pricing tactics. Until now, we didn’t know much more than the names of the 12 companies he sent letters to. But I dug around for more information ahead of the committee’s first hearing on the issue, on Jan. 29. Here’s what I learned: